PLAGL2 and breast cancer: EPSTI1 for breast cancer,16 AR for prostate cancer,15 GRAP for oral squamous cell carcinoma,17 CDCP1 and PLAGL2 for ovarian cancer were the only five direct targets identified for miR‐654‐5p thus far.